David Bearss

David Bearss

Company: Halia Therapeutics

Job title: Chief Executive Officer

Seminars:

Panel Discussion: What are the Future Directions of the Inflammasome Therapeutics Landscape? A Glimpse into the Next 5 Years 2:30 pm

Reflecting on all the incredible insights shared today and our key takings, where do we see the inflammasome landscape going? Does commercial opportunity lie in tackling metabolic diseases or even with combination therapies? What is the feasibility and efficacy of targeting alternative inflammasomes across diverse disease sets? Discuss the areas of unmet needs with opportunity…Read more

day: Day 2

Leveraging Inflammatory Induced Pain as an Innovative & Alternative Endpoint for a Time-Effective Measurement of Therapeutic Benefit 8:00 am

Examine the traditional endpoints used in clinical trials for inflammatory diseases and their limitations in demonstrating therapeutic efficacy within practical timeframes Exploring alternative endpoints that offer meaningful signals of therapeutic effectiveness while minimizing trial duration Detailing innovative approaches to optimize clinical trial outcomes, balancing the need for meaningful signals with cost-effective trial designRead more

day: Day 2

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.